L’ espressione di BIRC3 come predittore di resistenza alla chemioradioterapia neoadiuvante nell’adenocarcinoma del cardias e nel carcinoma squamoso dell’esofago

As part of a tailored treatment in the management of neoplastic diseases of the esophagus, we evaluated the possibility to identify a molecular marker of response to therapy. The expression of BIRC3 regulated by TAK1 may be responsible for resistance to neoadjuvant chemo-radiotherapy in the treatment of the esophageal and esophageal-gastric junction (EGJ) adenocarcinoma and does not seem to have a major role in squamous cell carcinomas.